Drug Information

Drug General Information
Drug ID
D00QEP
Former ID
DNCL002400
Drug Name
Inotuzumab ozogamicin
Drug Type
Antibody
Indication Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0] Approved [543021], [547545]
Company
Pfizer New York, NY
CAS Number
CAS 635715-01-4
Target and Pathway
Target(s) B-cell receptor CD22 Target Info [532335]
KEGG Pathway Cell adhesion molecules (CAMs)
Hematopoietic cell lineage
B cell receptor signaling pathway
PANTHER Pathway B cell activation
Pathway Interaction Database BCR signaling pathway
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways B Cell Receptor Signaling Pathway
References
Ref 543021(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8266).
Ref 547545Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017171)
Ref 532335Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.